News & Events
Tanvex BioPharma Completes Acquisition of Bora Biologics, Launching New Era in Biologics Development
SAN DIEGO, CA – January 20, 2025 – Tanvex BioPharma, Inc. (“Tanvex”), a contract development and manufacturing...
Bora Company Presentation at 43rd Annual J.P. Morgan Healthcare Conference
43rd Annual J.P. Morgan Healthcare Conference Bora Pharmaceuticals has been invited to participate in the prestigious...
Bora Biologics Announces Strategic Collaboration to Accelerate Key CMC Development of DotBio’s Tri-Specific Antibody to Treat Cancer
Bora Biologics Announces Strategic Collaboration to Accelerate Key CMC Development of DotBio’s Tri-Specific Antibody...
Bora Pharmaceuticals Announces Unveiling of New Multi-Purpose Small Molecule Site in Zhongli, Taiwan
Bora Pharmaceuticals Announces Unveiling of New Multi-Purpose Small Molecule Site in Zhongli, Taiwan Taipei, Taiwan...
Bora Pharmaceuticals Wins Dual Honors at the Taiwan MAPECT M&A Ceremony: “Deal of the Year” Award and “Best Cross-Border M&A” Award
Bora Pharmaceuticals Wins Dual Honors at the Taiwan MAPECT M&A Ceremony: "Deal of the Year" Award and "Best...
Bora Pharmaceuticals to Expand Rare Disease Portfolio with Acquisition of US-Based Pyros Pharmaceuticals
Taipei, Taiwan, October 25, 2024 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), today...
Bora Appoints J.D. Mowery As First Division President Of Its CDMO Business
Bora Appoints J.D. Mowery As First Division President Of Its CDMO Business TAIPEI, TAIWAN, October 3, 2024 –...
Tanvex Appoints Biopharma Industry Veteran Stephen Lam as CEO
Taipei, Taiwan - September 4, 2024 - Tanvex BioPharma, Inc. (“Tanvex” or “the Company”, TWSE: 6541), the...
Bora Pharmaceuticals Makes a Strategic Investment into Tanvex to Provide Global BioManufacturing Services.
Taipei, Taiwan, August 27, 2024 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), today...